Close Menu
Clark Law Firm A Professional Corporation
Call 24/7 Hablamos Español-Falamos Português
1-877-841-8855
  • Facebook
  • Twitter
  • LinkedIn

Lipitor

Mark Morris

Lipitor is currently one of the most commonly used brand-name medications for treating high cholesterol.  This cholesterol lowering medicine has generated an estimated $125 billion in sales for Pfizer before being made available as a generic medication in 2011.  Advertising campaigns have heavily steered prospective users to seek their doctor’s advice as to whether or not they should begin using Lipitor to maintain a healthy lifestyle.  These advertisements, while directed at the public in general, also targeted women who did not have many risk factors for heart disease and were not at high risk of a cardiac event.  Women in this class of Lipitor users allegedly received little to no long-term benefit from the use of Lipitor.

According to several lawsuits filed in 2013, complainants allege that Pfizer knew or reasonably should have known as early as 1997 that there was a correlation between Lipitor and Type 2 diabetes.  Several lawsuits allege that Pfizer was aware, or reasonably should have been aware of this correlation before Lipitor was even placed on the market and made available to the public.  Pfizer, however, allegedly did not place a warning of this potential correlation on Lipitor’s label until February of 2012.  Pfizer is alleged to have acted only once the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products requested that a warning be placed on Lipitor to protect consumers and the medical community.

Once prompted to add a warning to their product’s label, the warning allegedly failed to actually mention a potential link between Type 2 diabetes, stating only that, “increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.”  Lawsuits allege that until a warning was added to Lipitor in February of 2012, Lipitor’s label never warned patients of any potential relation between changes in blood sugar levels and the use of the drug.

Furthermore, lawsuits allege that despite changing the label in Feburary of 2012, Pfizer continues to fail to adequately warn consumers of the potential risk of developing Type 2 diabetes from the use of Lipitor.  If you or a loved one has been harmed by the use of Lipitor, contact the Clark Law Firm, PC today.  Lipitor is one of the best selling drugs of all time; there is no excuse for the product’s manufacturer to not properly warn users of the potential side effects of their drug.  Act now.  If you believe you were injured by Lipitor, contact the New Jersey personal injury attorneys at the Clark Law Firm, PC today.

Share This Page:
Copy